Day: June 2, 2023

Series  RIKB 26 1015 RIKS 37 0115Settlement Date  06/07/2023 06/07/2023Total Amount Allocated (MM)  3,163 4,835All Bids Awarded At (Price / Yield)  95.900 / 8.170 88.547 / 1.967Total Number of Bids Received  20 20Total Amount of All Bids Received (MM)  3,663 5,985Total Number of Successful Bids  15 12Number of Bids Allocated in Full  15 12Lowest Price / Highest Yield Allocated  95.900 / 8.170 88.547 / 1.967Highest Price / Lowest Yield Allocated  96.040 / 8.120 89.050 / 1.922Lowest Price / Highest Yield Allocated in Full  95.900 / 8.170 88.547 / 1.967Weighted Average of Successful Bids (Price/Yield)  95.973 / 8.150 88.660 / 1.957Best Bid (Price / Yield)  96.040 / 8.120 89.050 / 1.922Worst Bid (Price / Yield)  95.790 / 8.210 88.187 / 2.000Weighted Average of All Bids Received (Price / Yield)  95.954 / 8.150 88.594 / 1.963Percentage...

2 June 2023 Announcement no. 33 Inside information Settlement – purchase of shares In connection with completion of Pharma Equity Group A/S’ (the “Company”) purchase of Reponex Pharmaceuticals A/S (“Reponex”), the new shares issued to former larger shareholders in Reponex were subject to a lock-up undertaking (the “Lock-Up Undertaking”). As a shareholder by mistake, and without having obtained consent from the Company, has divested shares in the Company in violation of the Lock-Up Undertaking, such shareholder has, as a consequence, undertaken towards the Company and the Company’s board of directors to buy back in the market minimum 6,795,163 shares (with a nominal value of DKK 1.0 each). The share purchase shall be completed no later than on 21 June 2023. For further information,...

Information on share capital and voting rights May 2023 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations.                          June 2nd, 2023 Statement made by:        Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)Date   Total number of shares   Total number of voting rightsTheorical (1) Exercisable (2)May 31st, 2023 43,753,380 43,753,380 43,706,473(1)   Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2)    For information, excluding treasury shares stripped of voting rights, excluding liquidity contract. Provision of Nexans articles...

Regulated informationIssy-les-Moulineaux, June 2nd, 2023 Monthly disclosure on share capital and voting rightsPursuant to Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorités des Marchés Financiers Registered name of the issuer: SODEXO255, quai de la Bataille de Stalingrad – 92130 ISSY-LES-MOULINEAUXDate Total number of shares Actual voting rights * Theoretical voting rights **May 31, 2023147,454,887216,543,857217,959,699* Actual voting rights: all of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than four years, which have double voting rights.** Theoretical voting rights: the number of theoretical voting rights is calculated based on the shares having either...

In parallel with the physical tests conducted in Terranet’s lab environment for the automotive vision system BlincVision, the company is setting up an advanced virtual environment to test how the system reacts in various traffic situations. -Before taking a test vehicle out on the road, we want to analyze different critical driving situations in a virtual test environment. By using a professional end-to-end simulation platform, we can validate the performance of each BlincVision component under realistic conditions, thus accelerating our hardware and software development, says Nihat Küçük CTO at Terranet. BlincVision is tested in a detailed 360° environment model that includes various urban scenarios, traffic situations, weather and lighting conditions, vehicle types, and module settings. The simulation is based on the most relevant safety-critical...

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She brings a wealth of global executive management, regulatory, and drug approval experience in five therapeutic areas including cancer drug development, during a ~ 30-year tenure at Bristol Myers Squibb Company. TAIPEI, Taiwan, June 02, 2023 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (TPEx: 4174) | Effective immediately, the OBI Pharma Board of Directors have appointed Heidi Wang, Ph.D. as Chief Executive Officer, a position previously held by Chairman and CEO, Yun Yen, MD. “We are excited that Dr. Wang has been appointed CEO of OBI Pharma to bring strategic vision and lead the organization with our innovative cancer therapeutics pipeline, towards successful...

Basel, Switzerland, 2 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting (“AGM”), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. For information on the agenda items and proposals of the board of directors as well as on how to attend the 2023 Annual General Meeting, exercise voting rights or issue voting instructions to the independent proxy, shareholders can access the invitation to the 2023 Annual General Meeting at https://ir.kinarus.com/2023-agm/. The annual report for the financial year 2022,...